{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:08:12Z","timestamp":1785305292372,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The BRAF<jats:sup>V600E<\/jats:sup> mutation is the most common genetic alteration in papillary thyroid carcinoma (PTC). In recent studies, the BRAF<jats:sup>V600E<\/jats:sup> mutation has been associated with poor clinicopathological characteristics, such as lymph node metastasis, extrathyroidal extension, and advanced stage. However, other studies have failed to establish an association between the BRAF<jats:sup>V600E<\/jats:sup> mutation and clinicopathological features. Therefore, we investigated the relationship between the BRAF<jats:sup>V600E<\/jats:sup> mutation and its clinicopathological factors at a single institution.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A total of 327 consecutive patients with PTC were enrolled in this study and underwent thyroid surgery at Yeouido St. Mary\u2019s Hospital between February 2010 and December 2011.<\/jats:p>\n            <jats:p>BRAF<jats:sup>V600E<\/jats:sup> mutation analysis was performed using polymerase chain reaction (PCR)-based amplification of DNA extracted from paraffin-embedded tumour specimens.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The BRAF<jats:sup>V600E<\/jats:sup> mutation was detected in the tumours of 241 (73.7%) patients. Lymph node metastasis, TNM stage, and multifocality were not significantly associated with the BRAF<jats:sup>V600E<\/jats:sup> mutation. However, larger tumour size, extrathyroidal extension, histologic type (classic type), and concurrent Hashimoto\u2019s thyroiditis were associated with the BRAF<jats:sup>V600E<\/jats:sup> mutation in the univariate analysis, although no clinicopathological features were associated with the BRAF<jats:sup>V600E<\/jats:sup> mutation in the multivariate analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>There was no idependent prognostic factor associated with BRAF<jats:sup>V600E<\/jats:sup> mutation status in this study. The BRAF<jats:sup>V600E<\/jats:sup> mutation is unlikely to serve as a prognostic factor for PTC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1477-7819-11-99","type":"journal-article","created":{"date-parts":[[2013,5,20]],"date-time":"2013-05-20T10:16:34Z","timestamp":1369044994000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma"],"prefix":"10.1186","volume":"11","author":[{"given":"Yong-Seok","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ja-Seong","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo-Chan","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,5,20]]},"reference":[{"key":"1303_CR1","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1001\/jama.295.18.2164","volume":"295","author":"L Davies","year":"2006","unstructured":"Davies L, Welch HG: Increasing incidence of thyroid cancer in the United States, 1973\u20132002. JAMA. 2006, 295: 2164-2167. 10.1001\/jama.295.18.2164.","journal-title":"JAMA"},{"key":"1303_CR2","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1002\/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1","volume":"83","author":"SA Hundahl","year":"1998","unstructured":"Hundahl SA, Fleming ID, Fremgen AM, Menck HR: A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985\u20131995. Cancer. 1998, 83: 2638-2648. 10.1002\/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1.","journal-title":"Cancer"},{"key":"1303_CR3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","volume":"55","author":"DM Parkin","year":"2005","unstructured":"Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55: 74-108. 10.3322\/canjclin.55.2.74.","journal-title":"CA Cancer J Clin"},{"key":"1303_CR4","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J: Mutations of the BRAF gene in human cancer. Nature. 2002, 417: 949-954. 10.1038\/nature00766.","journal-title":"Nature"},{"key":"1303_CR5","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.beem.2008.09.017","volume":"22","author":"JA Fagin","year":"2008","unstructured":"Fagin JA, Mitsiades N: Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Pract Res Clin Endocrinol Metab. 2008, 22: 955-969. 10.1016\/j.beem.2008.09.017.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1303_CR6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S1535-6108(04)00087-X","volume":"5","author":"AS Dhillon","year":"2004","unstructured":"Dhillon AS, Kolch W: Oncogenic B-Raf mutations: crystal clear at last. Cancer Cell. 2004, 5: 303-304. 10.1016\/S1535-6108(04)00087-X.","journal-title":"Cancer Cell"},{"key":"1303_CR7","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/j.1365-2265.2005.02389.x","volume":"63","author":"TY Kim","year":"2005","unstructured":"Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, Kim SY, Kim SC, Hong SJ, Shong YK: The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf). 2005, 63: 588-593. 10.1111\/j.1365-2265.2005.02389.x.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1303_CR8","doi-asserted-by":"publisher","first-page":"818","DOI":"10.3349\/ymj.2004.45.5.818","volume":"45","author":"KH Kim","year":"2004","unstructured":"Kim KH, Kang DW, Kim SH, Seong IO, Kang DY: Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J. 2004, 45: 818-821.","journal-title":"Yonsei Med J"},{"key":"1303_CR9","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/SLA.0b013e318148563d","volume":"246","author":"E Kebebew","year":"2007","unstructured":"Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, Shibru D, Bastian B, Griffin A: The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg. 2007, 246: 466-470. 10.1097\/SLA.0b013e318148563d.","journal-title":"Ann Surg"},{"key":"1303_CR10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/j.1365-2265.2004.02089.x","volume":"61","author":"L Fugazzola","year":"2004","unstructured":"Fugazzola L, Mannavola D, Cirello V, Vannucchi G, Muzza M, Vicentini L, Beck-Peccoz P: BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf). 2004, 61: 239-243. 10.1111\/j.1365-2265.2004.02089.x.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1303_CR11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/cncr.22754","volume":"110","author":"JH Lee","year":"2007","unstructured":"Lee JH, Lee ES, Kim YS: Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer. 2007, 110: 38-46. 10.1002\/cncr.22754.","journal-title":"Cancer"},{"key":"1303_CR12","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1210\/er.2007-0007","volume":"28","author":"M Xing","year":"2007","unstructured":"Xing M: BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007, 28: 742-762. 10.1210\/er.2007-0007.","journal-title":"Endocr Rev"},{"key":"1303_CR13","first-page":"1454","volume":"63","author":"ET Kimura","year":"2003","unstructured":"Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA: High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET\/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003, 63: 1454-1457.","journal-title":"Cancer Res"},{"key":"1303_CR14","first-page":"152","volume":"1795","author":"C Nucera","year":"2009","unstructured":"Nucera C, Goldfarb M, Hodin R, Parangi S: Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E). Biochim Biophys Acta. 2009, 1795: 152-161.","journal-title":"Biochim Biophys Acta"},{"key":"1303_CR15","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1210\/jc.2008-2390","volume":"94","author":"H Guan","year":"2009","unstructured":"Guan H, Ji M, Bao R, Yu H, Wang Y, Hou P, Zhang Y, Shan Z, Teng W, Xing M: Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab. 2009, 94: 1612-1617. 10.1210\/jc.2008-2390.","journal-title":"J Clin Endocrinol Metab"},{"key":"1303_CR16","doi-asserted-by":"publisher","first-page":"6373","DOI":"10.1210\/jc.2005-0987","volume":"90","author":"M Xing","year":"2005","unstructured":"Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW: BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005, 90: 6373-6379. 10.1210\/jc.2005-0987.","journal-title":"J Clin Endocrinol Metab"},{"key":"1303_CR17","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1210\/jc.2007-1179","volume":"92","author":"C Lupi","year":"2007","unstructured":"Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M, Materazzi G, Elisei R, Santoro M, Miccoli P, Basolo F: Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2007, 92: 4085-4090. 10.1210\/jc.2007-1179.","journal-title":"J Clin Endocrinol Metab"},{"key":"1303_CR18","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00428-005-1236-0","volume":"446","author":"V Trovisco","year":"2005","unstructured":"Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, Maximo V, Botelho T, Moreira S, Meireles AM, Magalhaes J, Abrosimov A, Cameselle-Teijeiro J, Sobrinho-Simoes M: Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients\u2019 age but not with tumour aggressiveness. Virchows Arch. 2005, 446: 589-595. 10.1007\/s00428-005-1236-0.","journal-title":"Virchows Arch"},{"key":"1303_CR19","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1677\/ERC-07-0212","volume":"15","author":"F Frasca","year":"2008","unstructured":"Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, Loda M, Vella V, Giordano C, Trimarchi F, Mazzon E, Belfiore A, Vigneri R: BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer. 2008, 15: 191-205. 10.1677\/ERC-07-0212.","journal-title":"Endocr Relat Cancer"},{"key":"1303_CR20","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/path.1736","volume":"205","author":"N Powell","year":"2005","unstructured":"Powell N, Jeremiah S, Morishita M, Dudley E, Bethel J, Bogdanova T, Tronko M, Thomas G: Frequency of BRAF T1796A mutation in papillary thyroid carcinoma relates to age of patient at diagnosis and not to radiation exposure. J Pathol. 2005, 205: 558-564. 10.1002\/path.1736.","journal-title":"J Pathol"},{"key":"1303_CR21","first-page":"4561","volume":"63","author":"X Xu","year":"2003","unstructured":"Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA: High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 2003, 63: 4561-4567.","journal-title":"Cancer Res"},{"key":"1303_CR22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1507\/endocrj.K08E-208","volume":"56","author":"Y Ito","year":"2009","unstructured":"Ito Y, Yoshida H, Maruo R, Morita S, Takano T, Hirokawa M, Yabuta T, Fukushima M, Inoue H, Tomoda C, Kihara M, Uruno T, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Miyauchi A: BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J. 2009, 56: 89-97. 10.1507\/endocrj.K08E-208.","journal-title":"Endocr J"},{"key":"1303_CR23","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/j.1440-1827.2005.01866.x","volume":"55","author":"KH Kim","year":"2005","unstructured":"Kim KH, Suh KS, Kang DW, Kang DY: Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto\u2019s thyroiditis. Pathol Int. 2005, 55: 540-545. 10.1111\/j.1440-1827.2005.01866.x.","journal-title":"Pathol Int"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1477-7819-11-99.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T23:47:03Z","timestamp":1630540023000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/1477-7819-11-99"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,20]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["1303"],"URL":"https:\/\/doi.org\/10.1186\/1477-7819-11-99","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,20]]},"assertion":[{"value":"15 January 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"99"}}